NCT01661881 2026-04-08
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT03623373 2026-03-30
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Washington University School of Medicine
Phase 2 Completed
NCT02446236 2026-03-24
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Hackensack Meridian Health
Phase 1 Active not recruiting
NCT02601313 2026-03-18
ZUMA-2
Gilead Sciences
Phase 2 Completed
NCT02213913 2026-03-11
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
Phase 1/2 Completed
NCT02339922 2026-03-05
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Active not recruiting
NCT04282018 2026-02-20
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
BeOne Medicines
Phase 1/2 Completed
NCT02213926 2026-02-10
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Acerta Pharma BV
Phase 2 Active not recruiting
NCT04849416 2026-02-06
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Eli Lilly and Company
Phase 2 Completed
NCT03932331 2026-01-29
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
AstraZeneca
Phase 1/2 Active not recruiting